Ligand Pharmaceuticals | LGND - Equity Capital And Reserves


Ligand Pharmaceuticals reported $1.02B in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Agenus USD -271.11M 3.03M Dec/2025
Amgen USD 8.66B 961M Dec/2025
Anika Therapeutics USD 143.46M 3.34M Dec/2025
Arrowhead Research USD 568.42M 102.37M Dec/2025
Baxter International USD 6.13B 1.11B Dec/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Eli Lilly USD 26.54B 2.74B Dec/2025
Enanta Pharmaceuticals USD 126.59M 61.87M Dec/2025
Enviri Corporation USD 255.06M 106.02M Dec/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
GlaxoSmithKline GBP 16.38B 229M Dec/2025
Glaxosmithkline GBP 22.06B 360M Dec/2025
Heron Therapeutics USD 13.28M 1.6M Dec/2025
Insmed USD 738.98M 206.6M Dec/2025
Intrexon USD 43.17M 75.33M Jun/2024
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
Karyopharm Therapeutics USD -269.26M 30.33M Sep/2025
Ligand Pharmaceuticals USD 1.02B 67.04M Dec/2025
MacroGenics USD 55.59M 11.41M Dec/2025
Merck USD 51.85B 2.79B Sep/2025
Pacira USD 693.11M 34.1M Dec/2025
Pfizer USD 92.8B 4.11B Sep/2025
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Veracyte USD 1.26B 36.61M Sep/2025